An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study.
暂无分享,去创建一个
Eric Boerwinkle | Lloyd E Chambless | Josef Coresh | Gerardo Heiss | E. Boerwinkle | A. Folsom | L. Chambless | A. Sharrett | P. Sorlie | J. Coresh | G. Heiss | T. Mosley | C. Ballantyne | T. Mosley | K. Wu | Kenneth K. Wu | A. R. Sharrett | A Richey Sharrett | Aaron R Folsom | Thomas H Mosley | Christie M Ballantyne | Guoqing Diao | Kenneth K Wu | Paul Sorlie | G. Diao | J. Coresh
[1] Ose,et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .
[2] J. Polak,et al. C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women: The Cardiovascular Health Study , 2005, Circulation.
[3] A. Folsom,et al. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. , 2000, Archives of internal medicine.
[4] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[5] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[6] A. Folsom,et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. , 2003, Journal of clinical epidemiology.
[7] A. Folsom,et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. , 1998, Circulation.
[8] Guoqing Diao,et al. Estimation of time‐dependent area under the ROC curve for long‐term risk prediction , 2006, Statistics in medicine.
[9] Vilmundur Gudnason,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.
[10] A. Hofman,et al. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. , 2003, Archives of internal medicine.
[11] C. Meisinger,et al. C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score: Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany , 2004, Circulation.
[12] G. Campbell,et al. Advances in statistical methodology for the evaluation of diagnostic and laboratory tests. , 1994, Statistics in medicine.
[13] W. Barlow,et al. Robust variance estimation for the case-cohort design. , 1994, Biometrics.
[14] G. Dagenais,et al. Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study. , 2005, Atherosclerosis.
[15] A. Folsom,et al. Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. , 1999, American journal of epidemiology.
[16] B. Efron,et al. Bootstrap confidence intervals , 1996 .
[17] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[18] E. Boerwinkle,et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. , 1997, Circulation.
[19] R. D'Agostino,et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.
[20] V. Salomaa,et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atheroscierosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study , 1999, The Lancet.
[21] J. Mckenney,et al. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.
[22] V. Salomaa,et al. Prospective Study of Fibrinolytic Factors and Incident Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[23] Heejung Bang,et al. Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study , 2004, Circulation.
[24] M. Rutter,et al. C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study , 2004, Circulation.
[25] Paul Schoenhagen,et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. , 2005, The New England journal of medicine.
[26] A. Folsom,et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. , 1996, Journal of clinical epidemiology.
[27] A. Folsom,et al. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. , 1989, American journal of epidemiology.
[28] J. Auer,et al. C-reactive protein and coronary artery disease. , 2002, Japanese heart journal.
[29] Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.